Essex company awarded £1.05 million towards improving treatment for diabetes care

Diabetes careArecor Ltd, a leading biopharmaceutical company, has been awarded £1.05 million towards its development of a ready to use glucagon pen for diabetic patients. The funding will support continued preclinical development of Arecor’s proprietary stable liquid glucagon that will replace glucagon powder and speed up the treatment process for diabetic patients with hypoglycaemia.

“Using Arecor's technology, we have been able to solve the very significant and elusive formulation challenge of developing a stable liquid glucagon product that will enable us to deliver a ready-to-use pen to rescue a hypo more quickly and effectively."

Dr Sarah Howell, CEO, Arecor Limited

Improving and simplifying diabetes care process

Diabetes careArecor have been working with the Juvenile Diabetes Research Foundation (JDRF) charity and patient groups to ensure their pen significantly improves and simplifies the administration of this life saving treatment and reduces a major source of anxiety for those living with type 1 and 2 diabetes.

The funding that has been awarded to Arecor from Innovate UK’s funding competition will be used for initiation human trials of the product. The funding is part of a government funding competition which has awarded over £1.8 billion to innovative science projects since 2007.

"We are delighted to receive this prestigious award from Innovate UK which will support the acceleration of our proprietary glucagon rescue treatment towards the clinic and first-in-human phase 1 trials”.

Dr Sarah Howell, CEO, Arecor Limited

Focusing on improved treatments for diabetes care

Research laboratoryArecor, a spin out from Unilever in 2007, is developing a portfolio of products to enable improved treatments for diabetes care. Arecor has partnered with the world’s largest pharmaceutical and biotech companies such as Glaxo Smith Kline (GSK), Genzyme, GALVmed, to enable previously impossible delivery and use options for biologics. In over 90 per cent of the cases – Arecor’s technology can enable…

  • solid-to-liquid re-formulations
  • improved stability
  • high-concentration delivery, e.g. 200+ mg/ml
  • co-formulation of incompatible components

Expanding facilities for research and development

Chesterford Research ParkArecor is the latest company to move to Chesterford Research Park where they have recently signed a five year lease on a 10,000sq ft (929sq m) facility having outgrown their 5000 sq ft facility on the Cambridge Science Park. This is twice the size of the company’s previous premises and allows the company to expand their research and development (R&D) facilities.

The company joined major bioscience players such as AstraZeneca and Domainex who have all chosen Chesterford as the base from which to advance their research and development. Chesterford is a key location within the ‘London-Stansted-Cambridge Corridor’ – identified as an emerging growth area for life sciences businesses. These location advantages are combining to make Essex a significant centre of life sciences research and innovation.

Working with INVEST Essex

INVEST Essex worked with Arecor on their choice of site; a 10,000sq ft (929sq m) facility incorporating an office and a research and development (R&D) space.

INVEST Essex also introduced Arecor to Uttlesford District Council who were able to provide support to the company with their Business Development Rate Relief Scheme. Arecor are now in the process of developing commercial collaborations which INVEST Essex will offer support with.

For more information on INVEST Essex see here.

Source [Diabetes] [GEN News]

Dave Russell-Graham
Dave Russell-Graham

Inward Investment Manager (Life Sciences)

+44 (0) 7881 310776

Biography

With over 30 years’ experience in the life sciences and healthcare sector Dave has an extensive range of contacts in the industry as well as experience in pharmaceutical development through to facility refurbishment and fit out. Dave’s work has predominantly been with major pharmaceutical companies, and in 2011 he was a key player in the deal between Pfizer and Mylan for Pfizer’s respiratory technology platform. More recently he has worked as the Scientific Development Advisor for Harlow Science Park.

Robert Edge
Robert Edge

Inward Investment Manager (UK Multimodal Gateway:Essex)

+44 (0) 7740 179497

Biography

Following a ten year career with a major Colchester freight forwarder shipping everything from confectionery to oxygen plants, Robert has spent almost 15 years in inward investment promotion. Having had experience in China, India and the Middle East, Robert leads on the logistics and renewables sector.